Table 1 Cell line characteristics, BRAF V600E mutational status and viability after sorafenib treatment for 48Â hours of all thyroid carcinoma cell lines examined
Cell line | Origin | BRAFV600E-mutation | IC50 sorafenib (μM) | Lowest effective concentration (μM) |
|---|---|---|---|---|
BHT101 | Papillary | Heterozygous | 2.1 | 1.0 |
B-CPAP | Papillary | Heterozygous | 1.85 | 1.0 |
TPC1 | Papillary | No | 2.6 | 0.05 |
FTC133 | Follicular | No | 2.9 | 1.0 |
FTC236 | Follicular | No | 3.2 | 0.5 |
FTC238 | Follicular | No | 4.2 | 0.01 |
ML1 | Follicular | No | 2.95 | 2.0 |
TT2609 | Follicular | No | 3.05 | 1.0 |
SW1736 | Anaplastic | Heterozygous | 3.25 | 1.0 |
HTh83 | Anaplastic | No | 3.95 | 2.0 |
C643 | Anaplastic | No | 3.2 | 0.01 |
HTh7 | Anaplastic | No | 3.1 | 2.0 |